Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

28
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
28
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.1K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

21
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
21
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

201
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
201
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.6K
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

24
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of nonapeptide-pentapeptide mixture as a novel food pursuant to regulation (EU) 2015/2283.

EFSA journal. European Food Safety Authority·2026
Same author

Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA journal. European Food Safety Authority·2026
Same author

Safety evaluation of blue galdieria extract as a food additive.

EFSA journal. European Food Safety Authority·2026
Same author

Safety of 3'-sialyllactose (3'-SL) sodium salt produced with a derivative strain (<i>Escherichia coli</i> K-12 MG1655 INB-3SL_01) of <i>E. coli</i> K-12 MG1655 (ATCC 700926) as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA journal. European Food Safety Authority·2026
Same author

Safety of carbon dioxide extract from <i>Cannabis sativa</i> L. as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA journal. European Food Safety Authority·2026
Same author

Re-evaluation of agar (E 406) as a food additive.

EFSA journal. European Food Safety Authority·2026

Related Experiment Video

Updated: Oct 18, 2025

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay
06:25

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay

Published on: January 12, 2024

1.7K

Benchmark dose-response analyses for multiple endpoints in drug safety evaluation.

Antero Vieira Silva1, Joakim Ringblom1, Peter Moldeus1

  • 1Unit of Integrative Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Toxicology and Applied Pharmacology
|October 4, 2021
PubMed
Summary

Benchmark dose (BMD) modeling offers a more informative approach to pharmaceutical safety assessment than the traditional no-observed-adverse-effect-level (NOAEL) method. This advanced technique provides better toxicity characterization and supports reducing animal testing in drug development.

Keywords:
Benchmark dose modelingHazard characterizationPharmaceutical developmentSafety assessmentToxicity testing

More Related Videos

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.4K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Related Experiment Videos

Last Updated: Oct 18, 2025

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay
06:25

Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay

Published on: January 12, 2024

1.7K
Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.4K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Area of Science:

  • Pharmacology and Toxicology
  • Drug Development
  • Regulatory Science

Background:

  • Hazard characterization is crucial in pharmaceutical development to identify drug risks and dose-response relationships.
  • The traditional no-observed-adverse-effect-level (NOAEL) approach identifies the highest non-adverse dose.
  • Benchmark dose (BMD) modeling, widely used in other regulatory fields, has not been extensively examined for pharmaceutical development.

Purpose of the Study:

  • To apply BMD modeling to various endpoints in sequential in vivo drug development studies.
  • To compare BMD modeling with the NOAEL approach for pharmaceutical safety assessment.
  • To evaluate the utility of BMD modeling in characterizing potential drug toxicity.

Main Methods:

  • BMD modeling was applied to all endpoints across three sequential in vivo studies.
  • Standardized critical effect size (CES) of 5% was used for endpoint comparison.
  • BMD results were compared against study NOAEL and the General Theory of Effect Size.

Main Results:

  • BMD modeling provided more informative dose-effect estimates compared to the NOAEL approach.
  • BMD modeling effectively handled effects occurring below the lowest tested dose and NOAEL.
  • The approach proved advantageous for characterizing potential toxicity in safety assessments.

Conclusions:

  • BMD modeling is a valuable tool for pharmaceutical hazard characterization, offering advantages over the NOAEL approach.
  • Its application can lead to significant reductions and refinements in animal testing by yielding more data from fewer animals.
  • BMD modeling is suitable as a substitute or complement to the NOAEL approach in safety assessments.